Company intelligence / Profile preview

Wandercraft

Paris, Île-de-France, Franceen.wandercraft.eu ↗

Ownership: Private
Employees: ~128
Development stage: Other

Overview

Wandercraft’s Atalante X robotic exoskeleton has CE marking and FDA clearance for use in rehabilitation centers for patients with motor paraplegia and hemiplegia. The company’s next-generation product, Eve—a self-balancing personal exoskeleton—is entering pivotal clinical trials in the US with plans for commercial launch by 2026. Over a hundred units are deployed globally across four continents, showing strong adoption and revenue growth.

Therapeutic areas: Neurology
Modalities: Device (Robotic exoskeleton)Non-pharmacological therapy (Rehabilitation device)
Industry: Therapeutic Medical Devices

Partnerships

Renault Group (strategic partnership/minority stake to scale up production)

Beyond the preview

Go deeper on Wandercraft.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wandercraft.

Explore the full profile